Resistance to TGF-b is frequently observed in ovarian cancer, and disrupted TGF-b/SMAD4 signaling results in the aberrant expression of downstream target genes in the disease. Our previous study showed that ADAM19, a SMAD4 target gene, is downregulated through epigenetic mechanisms in ovarian cancer with aberrant TGF-b/SMAD4 signaling. In this study, we investigated the mechanism of downregulation of FBXO32, another SMAD4 target gene, and the clinical significance of the loss of FBXO32 expression in ovarian cancer. Expression of FBXO32 was observed in the normal ovarian surface epithelium, but not in ovarian cancer cell lines. FBXO32 methylation was observed in ovarian cancer cell lines displaying constitutive TGF-b/SMAD4 signaling, and epigenetic drug treatment restored FBXO32 expression in ovarian cancer cell lines regardless of FBXO32 methylation status, suggesting that epigenetic regulation of this gene in ovarian cancer may be a common event. In advanced-stage ovarian tumors, a significant (29.3%; Po0.05) methylation frequency of FBXO32 was observed and the association between FBXO32 methylation and shorter progression-free survival was significant, as determined by both Kaplan-Meier analysis (Po0.05) and multivariate Cox regression analysis (hazard ratio: 1.003, Po0.05). Reexpression of FBXO32 markedly reduced proliferation of a platinum-resistant ovarian cancer cell line both in vitro and in vivo, due to increased apoptosis of the cells, and resensitized ovarian cancer cells to cisplatin. In conclusion, the novel tumor suppressor FBXO32 is epigenetically silenced in ovarian cancer cell lines with disrupted TGFb/SMAD4 signaling, and FBXO32 methylation status predicts survival in patients with ovarian cancer. Ovarian cancer is the fifth leading cause of death in women and the most deadly of gynecological malignancies.
Ovarian cancer is the fifth leading cause of death in women and the most deadly of gynecological malignancies. 1 The lifetime risk of ovarian cancer in women is B1.5%. 2 As ovarian cancer has few symptoms early in its course, the majority of patients are diagnosed with advanced-stage disease. Despite advances in chemotherapy, the poor prognosis for patients with ovarian cancer is reflected in the o20% 5-year survival rate after initial diagnosis for patients with stage III and IV disease, whereas survival of patients with stage I or II disease is 480% for the same period. 3 Current prognostic indicators using clinicopathological variables, including stage and grade, neither accurately predict clinical outcomes nor provide biological insight into the disease. Thus, a better understanding of the molecular carcinogenesis of ovarian cancer is required for developing more reliable prognostic markers. The transforming growth factor-b signaling pathway has an important role in controlling proliferation, differentiation, and other cellular processes, including the growth of ovarian surface epithelial (OSE) cells. 4 With each ovulation, the OSE covering the ovary undergoes rupture, followed by proliferation-mediated repair. 5 The growth inhibitory effect of TGF-b on the OSE may have a key role in preventing overproliferation of OSE, 5 and dysregulation of TGF-b signaling may be crucial to the development of epithelial ovarian cancer. In addition, resistance to TGF-b signaling is commonly observed in ovarian cancer, 6, 7 suggesting that diminished responsiveness to TGF-b is a key event. However, few studies have examined the consequences of disrupted TGF-b signaling in ovarian cancer.
Ovarian tumorigenesis is a multistep process that includes the accumulation of acquired (somatic) epigenetic changes in critical genes. 8 Epigenetic alterations, including DNA methylation and histone modifications, have important roles in gene regulation, [9] [10] [11] and we along with others [12] [13] [14] [15] [16] have previously shown that tumor-suppressor genes can be transcriptionally silenced by epigenetic modifications in ovarian cancer. We have also shown that epigenetically modified genes can be used for both ovarian cancer diagnosis and prognosis. 17, 18 Our previous study using chromatin immunoprecipitation microarray (ChIP-Chip) identified FBXO32 as a TGF-b/SMAD target gene in OSE.
19 FBXO32 (also known as atrogin-1) is a member of the F-box protein family and constitutes one of the four subunits of the ubiquitin protein ligase complex. 20, 21 The FBXO32 protein has been reported to have a role in muscle atrophy, 22 and recent findings suggest that FBXO32 is a novel apoptosis regulator 23 and is negatively regulated by a prosurvival signal. 24 Interestingly, Tan et al 23 also showed that FBXO32 was transcriptionally silenced by epigenetic mechanisms in MCF-7 breast cancer cells. In this study, we found that FBXO32 was downregulated in a panel of ovarian cancer cell lines. Promoter hypermethylation of FBXO32 was observed in ovarian cancer cells, showing constitutive SMAD4 nuclear translocation. 15 Restoration of FBXO32 suppressed ovarian cancer cell growth in vitro and xenografts in vivo; this suppression was due to increased apoptosis. FBXO32 resensitized drug-resistant ovarian cancer cells to cisplatin. Importantly, ovarian cancer patients with high FBXO32 methylation had significantly shorter progression-free survival (PFS) than patients with no or low methylation. These results suggest that dysregulation of TGF-b/SMAD4 signaling may lead to aberrant DNA methylation of FBXO32 in ovarian cancer. FBXO32 may be a novel tumor suppressor, and the methylation status of FBXO32 may predict survival in ovarian cancer.
MATERIALS AND METHODS Patient Samples
A total of 96 ovarian cancer samples were obtained from the Tri-Service General Hospital (Taipei, Taiwan) (Supplementary Table S1 ). Five normal OSE (NOSE) cells were acquired from patients during surgery for benign gynecological disease at the Indiana University as described previously. 17, 25 All studies involving human ovarian epithelial samples were approved by the Institutional Review Boards of the Tri-Service General Hospital (Taiwan) and the Indiana University.
Cell Culture and Epigenetic Treatment
Immortalized OSE (IOSE) cells were derived by transducing the catalytic subunit of human telomerase and the papilloma virus subunit E7 into primary ovarian epithelial cells, as described previously. 26 Cells were maintained in a 1:1 mixture of medium 199 (Sigma, St Louis, MO, USA) and 105 (Sigma) supplemented with 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA, USA), 400 ng/ml hydrocortisone (Sigma), 10 ng/ml EGF, and 50 Units/ml of penicillin/streptomycin (Invitrogen). 26 Ovarian cancer cell lines, namely A2780, CP70, MCP2, MCP3, were propagated with RPMI 1640 (Invitrogen) containing 10% FBS. The HeyC2 cell was cultured with DMEM containing 5% FBS, 1% NEAA, 1% Gln, and 1% HEPES. The SKOV3 cell was cultured with McCoy's 5A containing 10% FBS, 1% NEAA, 1% Gln, and 1% HEPES. For epigenetic treatment, 1 Â 10 6 cells were seeded onto 90-mm plates and treated with 5 mM 5 0 -aza-2 0 -deoxycytidine (5-azaDC; Sigma) for 72 h or with trichostatin A (TSA, 0.5 mM; Sigma) for 12 h. For 5-azaDC treatment, media were changed and a new drug was added every 24 h.
DNA Extraction
DNA was extracted using the Tissue and Cell Genomic DNA Purification Kit (Genemark, Taiwan). DNA was eluted in 50 ml distilled water and stored at À201C until use.
Bisulfite Conversion and Combined Bisulfite Restriction Analysis
Genomic DNA (0.5 mg) was bisulfite modified using the EZ DNA Methylation Kit (Zymo Research, Orange, CA, USA) according to the manufacturer's protocol. For combined bisulfite restriction analysis (COBRA), bisulfite-modified DNA was first amplified using FBXO32-specific primer, followed by digestion with 20 Units of AciI (GGCG) or Hinp1I (GCGC) (New England Biolabs, Ipswich, MA, USA). FBXO32-specific primers were: forward primer, 5 0 ATTGG TTAGTGATAGTTAAGGGGT and reverse primer, 5 0 GGGAT AACGGTGTTTTGG (369 bp). After bisulfite conversion of methylated original genomic sequence, multiple sites for each of these enzymes were present; however, no sites were present in the bisulfite-converted original unmethylated genomic sequence. The digested PCR products were separated by gel electrophoresis using 3% GenePure high-resolution agarose (ISC BioExpress, Kaysville, UT, USA) and stained with ethidium bromide.
Methylation-Specific PCR and Real-Time Quantitative Methylation-Specific PCR The bisulfite-modified DNA was subjected to methylationspecific PCR (MSP) and real-time quantitative MSP (qMSP) as described previously. 27 Primers targeting the promoter region of FBXO32 were as follows: forward, 5 0 TTAGTTTT GCGGACGGTTC and reverse, 5 0 CGGGGCGTATTTTTTT AAGC (187 bp). For qMSP, b-actin (ACTB) or collagen (COL2A1) were used to normalize for the input DNA. A region devoid of any CpG dinucleotide was amplified using the following primer sequences: for ACTB, forward primer 5 0 TGGTGATGGAGGAGGTTTAGTAAGT and reverse primer 5 0 AACCAATAAAACCTACTCCTCCCTTAA (133 bp); for COL2A1, forward primer 5 0 TCTAACAATTATAAACTCCAA CCACCAA and reverse primer 3 0 GGGAAGATGGGATAGA AGGGAATAT. The amount of methylated FBXO32, ACTB, and COL2A1 were determined by the threshold cycle number (C t ) for each sample against a standard curve generated by SssI-treated DNA-MSP cloned fragment. The percentage of FBXO32 methylation was calculated as the FBXO32:ACTB or FBXO32:COL2A1 ratio of a sample divided by the same ratio of SssI-treated sperm DNA (Millipore, Billerica, MA, USA) and multiplied by 100.
RNA Extraction and Quantitative Reverse
Transcription-PCR Total RNA from cell lines was extracted using Trizol (Invitrogen) as described previously. 28 In brief, 1 mg of total RNA was treated with DNase I (amplification grade, Invitrogen) before first-strand cDNA synthesis using reverse transcriptase (Superscript II RT, Invitrogen). PCR reactions were carried out using ABI 7500 real-time PCR system (Applied Biosystems, Foster city, CA, USA). FBXO32 and GAPDH cDNA were amplified with the following primer sequences: FBXO32 forward, 5 0 AAGTCTGTGCTGGTCGGG AA and reverse, 5 0 AGTGAAGGTGAGGCCTTTGAAG; GAPDH forward, 5 0 CCCCTTCATTGACCTCAACTACAT and reverse, 5 0 TCACCATCTTCCAGGAGCG. The relative expression of FBXO32 was calculated using comparative C t method.
Plasmid Construction and Colony-Formation Assay
The full-length human FBXO32 cDNA was cloned from IOSE cells. The fragment was inserted into the XhoI-BamHII sites of vector pIRES_EGFP (Promega, Madison, WI, USA) or pcDNA3.1 (Invitrogen). Plasmid constructs were verified by sequencing. Approximately 1.5 mg of FBXO32 expression vector or empty vector was transfected into CP70 or HeyC2 cells using Transfectam Reagent (Promega) according to the manufacturer's protocol. Twenty-four hours after transfection, cells were replated in triplicate and cultured for 3 weeks in RPMI 1640 containing 10% FBS supplemented with 400 mg/ml G418 (Invitrogen, Paisley, UK). The surviving colonies were stained with 0.4% crystal violet (Sigma) in 50% methanol, and visible colonies were counted. Experiments were repeated twice and the average number of colonies from six plates for each plasmid was obtained.
Cell Proliferation Assay
Cell growth was assessed by counting cell numbers or by MTS assay, as described previously. 15 In brief, for cell number counts, 5 Â 10 4 cells were seeded onto a 35-mm plate, and cell numbers were determined daily using a hemacytometer. For MTS assays, B1000 cells were seeded in 96-well plates for 4 days with or without various concentrations of cisplatin (Sigma). Cell growth was determined using the CellTiter 96 Aqueous One Solution Cell Proliferation Assay Kit (Promega), according to the manufacture's protocol. Relative cell numbers were assessed using a 96-well ELISA plate reader with an absorbance set at 490 nM.
Flow Cytometry Analysis
Cells were cultured with or without cisplatin (1 mg/ml) for 24 h, collected after brief trypsinization, washed with PBS, and fixed in 70% ethanol for 24 h at À201C. Cells were then treated with 0.1 mg/ml RNase, stained with 10 mg/ml propidium iodide (Sigma) at 371C for 30 min and analyzed using FACScan flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). The percentage of apoptotic cells in the sub-G1 area was analyzed using the software cell quest (Becton Dickinson). The cell-cycle distribution was quantified using the ModFit LT software (Becton Dickinson).
In vivo Tumorigenicity Assay A total of four, 8-week-old, athymic nude mice (BALB/ cByJNarl) were obtained from the National Laboratory Animal Center (Taiwan). All mice were kept under specific pathogen-free conditions using a laminar airflow rack with free access to sterilized food and autoclaved water. All experiments were conducted after obtaining license from the Animal Experimentation Ethics Committee of the National Chung Cheng University. Overall, 1 Â 10 5 cells of CP70 stably transfected with pcDNA3.1/FBXO32 or empty vector were resuspended in a mixture of 0.1 ml of medium and Matrigel (1:1) (BD Bioscience, San Jose, CA, USA). Cell suspension was then injected subcutaneously into the flank of each mouse (day 0). Tumor size was measured daily with calipers in length (L) and width (W). Tumor volume was calculated using the formula (L ÂW 2 /2). At the end of experiment, all mice were killed by cervical dislocation.
Immunohistochemistry
Paraffin-embedded tissues of the above-mentioned patient samples were retrieved from the Department of Pathology (Tri-Service General Hospitals, Taiwan). Tissue sections were dewaxed in xylene, rehydrated in alcohol, and immersed in 3% hydrogen peroxide for 10 min to suppress endogenous peroxidase activity. Antigen retrieval was performed by heating each section at 1001C for 30 min in 0.01 mol/l sodium citrate buffer (pH 6.0). After 5-min rinses three times in phosphate-buffered saline (PBS), sections were incubated for 1 h at room temperature with a mouse polyclonal anti-FBX32 antibody (ab67866, Abcam, Cambridge, UK) diluted 1:100 in PBS, and bound antibodies were detected with a streptavidin-biotin-peroxidase system (Dako, Glostrup, Denmark) and 3,3 0 -diaminobenzidine substrate-chromogen solution (Dako). Slides were counterstained with hematoxylin and examined by an experienced pathologist (T-K Chao).
Statistical Analysis
Multivariate survival analysis was determined using Cox proportional hazards model with the DNA methylation level as a continuous variable. The multivariate Cox proportional hazards model was used to determine the independent prognostic value of DNA methylation level, stage, and age. PFS) and overall survival (OS) were assessed by KaplanMeier analysis using log-rank test. PFS was defined as the duration from the day of diagnosis or chemotherapy to detection of new lesions or progression of residual lesions. OS was defined as the duration from the day of diagnosis to death. A DNA methylation level at 30% (level of methylation in OSE cells) was used as a cutoff. It is also noted that there were 37 patients with low methylation level (o15%) and low OS (o36 months). This extreme group of patients was excluded from some analysis as specified ( Supplementary Figure S4 ). Fisher's exact test or the Mann-Whitney U test was also used to compare parameters of different groups. All statistical calculations were carried out using statistical package SPSS version 13.0 for windows (SPSS, Chicago, IL, USA). Po0.05 was considered significant.
RESULTS

FBXO32 Expression Correlates with Promoter Methylation in Ovarian Cancer Cell Lines
On the basis of our recent ChIP-Chip experiment identifying FBXO32 as a candidate TGF-b/SMAD4 target in IOSE (Supplementary Figure S1) , 19 it was of interest to examine the expression of FBXO32 in a panel of ovarian cancer cell lines (namely HeyC2, SKOV3, MCP3, MCP2, A2780, and CP70). Low or no expression of FBXO32 mRNA was observed in all ovarian cancer cell lines as compared with IOSE cells (Figure 1 ). As a previous study showed that downregulation of FBXO32 correlated with promoter hypermethylation in breast cancer MCF-7 cells, 23 we examined whether FBXO32 was silenced by a similar mechanism in ovarian cancer. COBRA was first conducted to determine the methylation status of a 400-bp region of the promoter. Digestion with two different restriction enzymes consistently showed that FBXO32 was methylated in HeyC2 cells (Figure 2a ). High-resolution bisulfite sequencing of 32 CpG sites showed that HeyC2 was densely methylated in this region. Approximately 30% of methylation was observed in IOSE cells, whereas the rest of the cells were essentially free of methylation ( Figure 2b ).
Reexpression of FBXO32 After Epigenetic Drug Treatment of Ovarian Cancer Cells
To quantify the methylation level of FBXO32, we designed a new set of primers for real-time qMSP assay on the basis of the previously described bisulfite sequencing. Consistent with the COBRA and bisulfite sequencing results, a significantly higher level methylation of FBXO32 in HeyC2 cells compared with the other cancer (Figure 2c ) or normal (Supplementary Figure S2) ovarian cells was observed using qMSP. Treatment with either the demethylating agent 5azaDC (Figure 3a) or HDAC inhibitor TSA (Figure 3b ) lead to partial reexpression of FBXO32 in all ovarian cancer cells and prominent FBXO32 reactivation was observed in HeyC2, which had the highest level of FBXO32 methylation. Interestingly, cells without FBXO32 methylation (such as MCP2, MCP3, CP70, and A2780) showed higher levels of FBXO32 reactivation after TSA treatment compared with 5azaDC. To exclude the possibility that high-dose 5azaDC treatment had additional effects (other than DNA demethylation) in the HeyC2 line, cells were treated with 0.5 mM of the DNMT inhibitor. Although the lower drug concentration had no obvious effect on reexpression of FBXO32 (Supplementary Figure S3a) , bisulfite sequencing showed that 0.5 mM of 5azaDC resulted in partial FBXO32 demethylation as compared with complete demethylation at 5 mM of the treatment (Supplementary Figure S3b) . Taken together, these results further show that FBXO32 is silenced by promoter hypermethylation in HeyC2 cells and suggest that chromatin histone modifications, rather than DNA methylation, contribute to FBXO32 gene silencing in MCP2, MCP3, CP70, and A2780 ovarian cancer cell lines.
Restoration of FBXO32 Inhibits Growth of Ovarian Cancer Cells
Although a previous study showed that FBXO32 is a tumor suppressor in breast cancer, 23 the role of FBXO32 in ovarian Figure S4) resulted in a reduction of size and number of colonies being formed. RT-PCR analysis confirmed the expression of FBXO32 in these transient transfected cells (Figure 4c) . Interestingly, transfection with the pcDNA3.1 vector showed a higher level of FBXO32 expression corresponding to a 420-fold growth suppression as compared with the pIRES_EGFP, vector which showed a lower level of FBXO32 expression and a 3-fold growth suppression (based on the number of colonies formed). Similar results were observed in FBXO32 stable transfectants using MTS assays (Figure 5a and b).
Restoration of FBXO32 Inhibits Tumor Growth In Vivo
To further examine the effect of FBXO32 in CP70 cells in vivo, cells that were stably transfected with either FBXO32 cDNA or control vector (pcDNA3.1) were injected subcutaneously into nude mice. Tumor growth from cells injected with control vector was first observed at day 9 after injection of CP70 cells (Figure 5c Figure S5 ). Taken together, results from in vitro and in vivo indicate that FBXO32 might be a tumor suppressor in ovarian cancer.
FBXO32 Induces Apoptosis and Enhances Chemosensitivity to Cisplatin
Having shown that FBXO32 inhibited the growth of ovarian cancer, it was of interest to examine the mechanism associated with this inhibition. As a previous study showed that FBXO32 has a critical role in regulating apoptosis in breast cancer, 23 we investigated whether FBXO32 induces apoptosis in ovarian cancer. Results from the FACS analysis showed that transfection of FBXO32 enhanced apoptosis in CP70 cells as compared with vector control (apoptotic cell%, control: 2.55 ± 0.17; FBXO32: 10.72 ± 1.07, Po0.05; Figure 6a and b). We then investigated whether FBXO32 can enhance the activity of a known apoptotic agent, cisplatin, in CP70 cells. As expected, CP70 showed chemoresistance to this agent (Figure 6b ) as reported previously. 29 Interestingly, FBXO32 markedly enhanced apoptosis of CP70 at the same dose of cisplatin (apoptotic cell%, control: 3.28±0.24; FBXO32: 16.94±0.25, Po0.05). Furthermore, MTS cytotoxicity assay showed that transfection of FBXO32 induced an Btwofold increase in cisplatin sensitivity of CP70 cells (IC 50 , control: 1.447 mg/ml; FBXO32-1: 0.892 mg/ml, and Figure 6c) . Surprisingly, the same effect was not observed in HeyC2 cells, which have much higher drug resistance than do CP70 cells (IC 50 , HeyC2: 5.6 mg/ml, CP70: 2.2 mg/ml, and Supplementary Figure S6) . However, an increase in the G1 cell population was observed in FBXO32-transfected HeyC2 cells (Supplementary Table S2 ), suggesting that decreased cell-cycle progression may be responsible for the slower cell growth rate observed in those cells (Figure 5b ).
FBXO32 Methylation Predicts Survival in Ovarian Cancer Patients
To investigate the clinical relevance of our in vitro findings, we used qMSP and immunohistochemistry to examine FBXO32 methylation and expression in tumor samples (n ¼ 96) obtained from ovarian cancer patients (Supplementary Table S1 ). The median age at the time of diagnosis for this cohort was 52 years (range, 18-90 years). A total of 58 cases (60.4%) were at high stage (FIGO stage III and IV) and 38 cases (39.6%) were at low stage (FIGO stage I and II). A 30% methylation level was used as a cutoff to discriminate between clinicopathological parameters, on the basis of the level of methylation determined in NOSE cells. The methylation level of FBXO32 was significantly associated with high-stage patients (P ¼ 0.024; Figure 7a and Table 1 ). No association between FBXO32 methylation and age or grade was observed. On the other hand, samples with higher methylation had lower expression of FBXO32, although heterogeneous FBXO32 staining was observed (Supplementary Figure S7) . Kaplan-Meier survival curves showed that patients with high FBXO32 methylation had significantly shorter PFS (P ¼ 0.027) than patients with low FBXO32 methylation (Figure 7b ), indicating that FBXO32 methylation may serve as a prognostic indicator. Although FBXO32 methylation was not significantly associated with OS, the high methylation group tended to have shorter survival (Figure 7c , P ¼ 0.096).
Interestingly, there was a group of patients displaying low FBXO32 methylation (methylation o15%) and also low OS (o36 months) (Supplementary Figure S8) , indicating that tumorigenesis in this group of patients may be independent of FBXO32 methylation. Exclusion of this extreme group from the analysis resulted in a significant association of FBXO32 methylation with stage (P ¼ 0.007), and marginally with grade (P ¼ 0.052; Table 1 ).
As the above-mentioned approaches used a cutoff value and may have biased the data analysis, a multivariate analysis was performed to analyze FBXO32 methylation (on a continuous scale) and age for their predictive values on OS and PFS. The results from Cox proportional hazards model are shown in Table 2 . FBXO32 methylation was predictive of PFS (hazard ratio: 1.003, P ¼ 0.028) but not OS (P ¼ 0.095). As expected, age was also a significant prognostic factor for OS (P ¼ 0.011). Exclusion of the extreme group also resulted in a significant association of FBXO32 methylation with PFS (P ¼ 0.008) and OS (P ¼ 0.008), which is similar to the Kaplan-Meier analysis showing that high FBXO32 methylation levels are associated with shorter survival.
DISCUSSION
Dysregulation of TGF-b signaling pathway is a common event in ovarian cancer and crucial for ovarian cancer carcinogenesis. 4 Recent studies have further shown that disruption of an upstream signaling pathway regulator may result in transcriptional repression of a downstream target gene through epigenetic mechanisms, 15, 30 and our previous study showed that dysregulation of TGF-b/SMAD4 signaling lead to epigenetic silencing of its downstream target, ADAM19 in ovarian cancer cells with impaired SMAD4 nuclear translocation. 15 In this study, our investigation of another TGF-b/SMAD4 downstream target, FBXO32, further supports this hypothesis. We found that FBXO32 is expressed in normal OSE cells but downregulated in ovarian cancer cells. Although this downregulation was mediated through DNA methylation in HeyC2 cells showing constitutive SMAD4 nuclear translocation 15 (Supplementary Figure S9) , downregulation of FBXO32 in ovarian cancer cells with impaired SMAD4 nuclear translocation (MCP2, MCP3, A2780, and CP70) was independent of DNA methylation. 15 Methylation of FBXO32 in HeyC2 cells may be due to long-term, constitutive activation of SMAD4; however, the role of SMAD4 in the methylation of FBXO32 warrants further investigation. Furthermore, we observed the downregulation of another TGF-b/SMAD4 target, RunX1T1, by promoter hypermethylation in HeyC2 cells (data not shown). Although our studies on the role of TGF-b in RUNX1T1 hypermethylation are currently ongoing, this result suggests that dysregulation of the TGF-b signaling pathway may contribute to concurrent methylation of tumor-suppressor genes in cancer, a phenomenon known as CpG island methylator phenotype, CIMP.
31
In contrast, silencing of FBXO32 in ovarian cancer cells with impaired SMAD4 nuclear translocation seems to be mediated by chromatin histone changes (Figure 3b ), as we have observed for another TGF-b downstream target, ADAM19. 15 In support of this possibility, a previous study reported that inhibition of the polycomb-repressive complex 2 by DZNep restored expression of FBXO32 in MCF7 cells. We observed that treatment with TSA, which has been shown to remove repressive histone marks, restored FBXO32 expression in cells without FBXO32 methylation (MCP2, MCP3, A2780, and CP70). In contrast, treatment with the DNMT inhibitor 5azaDC did not result in the reexpression of FBXO32 in MCF7 cells, although partial demethylation was observed. 23 This discrepancy may be attributed to the fact that low-dose 5azaDC (0.5 mM) leads to only partial demethylation of FBXO32, whereas complete demethylation is required for the reactivation of this gene (Supplementary Figure S3) . However, it is possible that the mechanism of FBXO32 silencing in breast cancer cells may be different than in ovarian cancer, and off-target effects of 5azaDC cannot be overlooked. In support of this latter possibility, inhibition of G9a histone methyltransferase decreased histone H3K9 dimethylation, 32 and 5azaDC can upregulate genes without causing detectable demethylation, 33, 34 perhaps explaining the partial reactivation of FBXO32 by 0.5 mM of 5azaDC in MCP2 and MCP3 cells (data not shown).
FBXO32 belongs to the F-box protein family of the SCF ubiquitin protein ligase complex involved in muscle atrophy. 22 However, a previous study showed that the AKT signaling pathway negatively regulates FBXO32, 24 thus implying that it may also be involved in regulating cell survival. 23 More recently, FBXO32 has been shown to be upregulated by tumor necrosis factor, a signaling which is known to be involved in regulating apoptosis. 35 In this study, we found that restoration of FBXO32 reduced tumor growth in vitro and in vivo, perhaps because of increased cellular apoptosis. To further investigate this possibility, we restored FBXO32 expression in drug-resistant ovarian cancer cells and examined the ability of cisplatin to induce apoptosis. Interestingly, FBXO32 resensitized CP70 cells to cisplatin and markedly enhanced apoptosis. On the contrary, FBXO32 reexpression only caused a decrease in cell-cycle progression in HeyC2 cells, which have a much higher drug resistance than do CP70 cells, suggesting that the mechanism of FBXO32-mediated growth suppression differs in the two ovarian cancer cell lines. Together with recent findings that two other members of F-Box protein FBXW7 and FBX4 can function as tumor suppressors, 36, 37 FBXO32 may be a novel tumor suppressor in ovarian cancer, and downregulation of FBXO32 may impair TGF-b-mediated growth inhibition in ovarian cancer as observed in our previous study. 15 To explore the relationship between clinicopathological features and methylation of FBXO32, we performed qMSP on ovarian carcinomas. A high level of FBXO32 methylation was significantly associated with higher stage and shorter PFS, thus suggesting that silencing of FBXO32 may be crucial to ovarian cancer progression and may have the potential to serve as a new prognostic marker for the disease. It is important to note that a group of patients displayed low FBXO32 methylation and low OS. Excluding that group from the analysis resulted in a further significant association between stage, grade, and survival (both OS and PFS). It is unclear why the survival of this group of patients was independent of FBXO32 methylation, but one possibility could be that the TGF-b signaling pathway was disrupted in those tumors, as we have observed in ovarian cancer cell lines (impaired SMAD4 nuclear translocation was seen in MCP3, MCP2, A2780, and CP70 cell lines 15 ; Figure 2 ). In conclusion, we show that FBXO32 is epigenetically silenced in ovarian cancer cells with impaired TGF-b/SMAD4 signaling and may be a novel tumor suppressor in ovarian cancer. As a high level of FBXO32 methylation predicts survival in ovarian cancer patients, we suggest that FBXO32 may serve as a methylation biomarker for the disease. 
